Eli Lilly Shares Sold by Investment Firm

Vaughan Nelson Investment Management reduces stake in pharmaceutical giant

Apr. 2, 2026 at 11:37am

Got story updates? Submit your updates here. ›

Vaughan Nelson Investment Management L.P., an institutional investor, has reduced its holdings in Eli Lilly and Company (NYSE: LLY) by 13% in the fourth quarter, according to a recent 13F filing. The firm now owns 230,021 shares of the pharmaceutical company's stock, valued at $247.2 million.

Why it matters

This transaction provides insight into the investment strategies of Vaughan Nelson, a prominent institutional investor. The reduction in Eli Lilly's holdings may signal a shift in the firm's outlook on the pharmaceutical company or broader market conditions.

The details

According to the 13F filing, Vaughan Nelson Investment Management sold 34,339 shares of Eli Lilly and Company during the fourth quarter. The firm now holds a 2.4% stake in the company, making it the 4th largest position in its portfolio.

  • Vaughan Nelson Investment Management reduced its Eli Lilly holdings in the fourth quarter of 2026.

The players

Vaughan Nelson Investment Management L.P.

An institutional investor that manages a diversified portfolio of investments, including a significant stake in Eli Lilly and Company.

Eli Lilly and Company

A global pharmaceutical company headquartered in Indianapolis, Indiana, that researches, develops, manufactures, and commercializes a broad range of medicines and therapies.

Got photos? Submit your photos here. ›

The takeaway

This transaction highlights the dynamic nature of institutional investment strategies and the ongoing evaluation of pharmaceutical companies like Eli Lilly by major investors. The reduction in Vaughan Nelson's stake may prompt further analysis of Eli Lilly's performance and outlook by other market participants.